Valproate: a practical review of its uses in neurological and psychiatric disorders

References

• Fariello RG, Varasi M, Smith MC. Valproic acid: mechanism of action. In: Anti-epileptic drugs. 4th ed. Levy R, Matson R, Meldrum B (Eds.) Raven Press, New York, NY, USA 581–588 (1995).
   Google Scholar
• Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of Valproate. Frog. Neurobiol. 19,315–399 (1992).
   Google Scholar
• Godin Y, Heiner L, Mark J, Mandel P. Effect of di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. j Neurochem. 16,869–873 (1969).
   PubMedGoogle Scholar
• Loscher W Correlation between alternations in brain GABA metabolism and seizure excitability following administration of GABA aminotransferase inhibitors and valproic acid-a reevaluation Neurochem. Int. 3, 397–404 (1981).
   Google Scholar
• Power LJ, Backford J, John RA. An analysis of the kinetics of the inhibition rabbit GABA-transaminase by sodium N-dipropylacetate and some other simple carboxylic acids. Biochem. Pharmacol. 24, 267–270 (1975).
   Google Scholar
• Harvey PKB, Bradford HF, Davisson AN. The inhibitory effect of sodium n-dipropylacetate on the degenerative enzymes of the GABA shunt. FEBS Lett. 52F, 251–254 (1975).
   Google Scholar
• Mclean MJ, MacDonald RL. Sodium valproate but ethosuximate, produces use and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. .1. Pharmacol. Exp. Ther. 237, 1001–1011 (1986).
   Google Scholar
• Francesschetti S, Hamon B, Heinenmann U. The action of valproate on spontaneous epileptiform activity in the absence of synaptic transmission and on the evoked changes on (CA+) and (K+) in the hippocampal slice. Brain Res. 386, 1–11 (1986).
   Google Scholar
• Schechter PJ, Trainer Y, Grove J. Effect of N-dipropylacetate on amino acid concentration in mouse brain: correlation with anticonvulsant activity. I Neurochem. 3,1325–1327 (1978).
   Web of Science ®Google Scholar
• Depakote® ER package insert, Abbott Laboratories, USA (2001).
   Google Scholar
• Perruca E, Gatti G, Frigo GM. Disposition of sodium valproate in epileptic patients. Br.Clin. Pharmacol (5) 495–499 (1078).
   Google Scholar
• Bourgeois, B. Valproate, In: Pediatric epilepsy diagnosis ancl therapy 2ncl ed Pellock J, Dodson W, Bourgeois (Eds.), 433–447 (2001).
   Google Scholar
• Cloyd J, Kriel R, Jones-Saete C. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance and preference. j Pecliatc 8,411–415 (1986).
   Google Scholar
• Levy RII, Conraud B, Loiseau P et al. Meal-dependent absorption of enteric-coated sodium valproate. Epilepsia 21,273–280 (1980).
   PubMedGoogle Scholar
• Gugler R, Schell A, Eichelbaum M, Froscher W, Schulz HU. Disposition of valproic in man. Eur. j Clin. Phalmacol 12,125–132 (1977).
   PubMedGoogle Scholar
• Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin. Pharmacol Ther. 21,736–743 (1977).
   PubMed Web of Science ®Google Scholar
• Cloyd JC, Kriel RL. Bioavailability of rectal administered valproic acid syrup. Neurology 31,1348–1352 (1981).
   PubMed Web of Science ®Google Scholar
• Issakainen J. Pharmacokinetic aspects of sodium valproate suppositories. In: Pmceecling of the Forth International Symposium on Sodium Valproate, and Epilepsy International Congress and Symposium Series. Chadwick (Ed.), 152, 192–194 (1989).
   Google Scholar
• Thorpy MJ. Rectal valproate syrup and status epilepticus. Neurology 30,1113–1114 (1980).
   PubMedGoogle Scholar
• Holmes GB, Rosenfield WE, Graves NM. Absorption of valproic acid suppositories in human volunteers. Arch. Neural 46,906–909 (1989).
   Google Scholar
• Limdi NA, Faught E. The safety of rapid valproic infusion. Epilepsia 41(10), 1342–1345 (2000).
   PubMed Web of Science ®Google Scholar
• Venkataraman V, Wheless JW. Safety of rapid iv. infusion of valproate loading doses in epilepsy patients. Epilepsy Res. 35(2), 147–153 (1999).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Mattson RII, Benett DM, Swick CT Variable free and total valproic acid concentrations in sole- and multidrug therapy. Ther. Drug- Monit. 8,411–415 (1986).
   PubMedGoogle Scholar
• Abbott FS, Kassam J, Orr JM, Farrell K. The effect of aspirin on valproic acid metabolism. Clin. Pharmacol The': 40(1), 94–100 (1986).
   Google Scholar
• Loscher W, Nau HP Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharm. 24, 225–235 (1990).
   Google Scholar
• Kesterson JW, Granneman GR, Machinist JM. The hepatotoxisity of valproic acid and its metabolites in rats. I. Toxocologic, biochemical and histopathologic studies. Hepatology 4, 1143–1152 (1984).
   Google Scholar
• Cloyd JC, Fisher JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. Effect of age and anti-epileptic drugs on protein binding and intrinsic clearance. Clin. Phalmacol Ther. 53,22–29 (1993).
   Google Scholar
• Löscher W, Nau H, Marescaux C, Vergnes M. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur. Pharmac. 99,211-218 (1984).
   Google Scholar
• Silver JM, Shin C, McNarnara JO. Anti- epileptic effect of conventional anticonvulsants in the kindling model of epilepsy. Ann. Neuml. 29,356–363 (1991).
   Google Scholar
• Burgeois B, Beaumanoir A, Blajev B. Monotherapy with valprote in primary generalized epilepsy. Epilepsia 28\(Suppl. 2), S8—S11 (1987).
   Google Scholar
• Karceski S, Morrell M, Carpenter D. The expert consensus guideline series. Treatment of epilepsy. Epilepsy Behavior 2 (Suppl.), A1—A50 (2001).
   Google Scholar
• Villareal HJ, Wilder BJ, Willmore LJ et al. Effect of valproic acid in epilepsy on spike and wave discharges in patients with absence seizures. Neurology 28,886–891 (1978).
   PubMedGoogle Scholar
• Pisani F, Narbone MC, Trunfio C et al. Valproic acid-ethusuximade interaction: a pharmacokinetic study. Epilepsia 25(2), 229–233 (1984).
   PubMedGoogle Scholar
• Iivanainen M, Himberg J. Valproate and clonazepam in treatment of severe progressive myoclonus epilepsy. Arch. Neural 39,236–238 (1982).
   PubMedGoogle Scholar
• McCabe P, McNew C, Michael N. Effect of Divalproex-Lamotrigine combination therapy in frontal lobe seizures. Arch. Neural 58(8), 1264–1268 (2001).
   Google Scholar
• Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 55(4), 588–591 (2000).
   PubMed Web of Science ®Google Scholar
• Brodie M, Yuen A and 105 study group. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res. 26(3), 423–432 (1997).
   Google Scholar
• Pisani F, Oteri G, Russo M, Di Pierri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40(8), 1141–1149 (1999).
   PubMed Web of Science ®Google Scholar
• Mattson R, Cramer JA, Collins JF. A comparison of valproate with carbamezapine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl. I Med. 327,765–771 (1992).
   Google Scholar
• Reynolds E, Heller A, Chadwick D. Valproate versuscarbamazepine for seizures. N Engl. I Med. 328,207–208 (1993).
   PubMedGoogle Scholar
• Chez MG, Bourgeois BFD, Pippenger CE, Knowles WD. Pharmacodynamic interactions between phenytoin and valproate: individual and combined anti-epileptic and neurotoxic actions in mice. Clin. Neumphalmacol, 17,32–37 (1994).
   PubMed Web of Science ®Google Scholar
• Yuen AWC, Lang G, Wetherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. BE j Clin. Pharmacol 33,511–513 (1992).
   PubMed Web of Science ®Google Scholar
• Gidal BE, Andreson GD, Rutecki PR, Shaw R, Lanning A. Lack of effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res. 42,23–32 (2001).
   Google Scholar
• Levy RII, Morehead T, Morselli P et al Carbamazepineivalproic acid interaction in man and rhesus monkey. Epilepsia 33,511–513 (1984).
   Google Scholar
• Pavone L, Incorpora G, LaRosa M, LiVolti S, Mollica E Treatment of infantile spasms with sodium dipropylacetic acid. Dev. Med. Child Neural 23,454–461 (1981).
   PubMedGoogle Scholar
• Patel I, Levy R, Culler R. Phenobarbital- valproic acid interaction. Clin. Phac Thec 27(4), 515–521 (1980).
   Google Scholar
• Wagner ML, Graves NM, Leppik IE, Remmel RP, Ward DL, Shumaker RC. The effect of felbamate on valproate disposition. Epilepsia 32 (Suppl. 3), 15 (1991).
   Google Scholar
• Dhillon S, Rhichens A. Serum protein binding of diazepam and its displacement by valproic acid in vitt-a BE j Clin. Pham. 12(4), 591–520 (1980).
   Google Scholar
• Wheless JW Pediatric use of iv. and itramuscular phenytoin: I Pssions learned. J. Child Aim& (suppl), 11–14; 30–32 (1998).
   Google Scholar
• Noritoku DK, Mueed S. Intravenous loading of valproate for epilepsy. Clin. Neuropharmacol 22,101–106 (1999).
   Google Scholar
• Davis LL, Ryan W Adinoff B, Petty E Comprehensive review of the psychiatric use of valproate. j Clin. Psychopharm. 20 (Suppl. 1), 1S-17S (2000).
   Google Scholar
• Daikilic A, Diaz E, Baker CB, Peasall HB, Woods SW Effect of divalproex versus lithium on length of hospital stays among patients with bipolar disorder. Bych. Sci. 51(9), 1184–1186 (2000).
   Google Scholar
• Keck P, Taylor V, Tugrul K et al Valproate treatment of panic disorder in lactate-induced panic attacks. Biol. Psychiatry 33, 542–546 (1993).
   PubMedGoogle Scholar
• Wassef AA, Dott SG, Harris A et al Randomized, placebo-controlled pilot study of divolproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J. Clin. Psychopharm. 20(3), 357–361 (2000).
   Google Scholar
• Wassef A, Dott S, Harris A et al Critical review of GABA-ergic drugs in the treatment of schizophrenia. J. Clin. PTchopharmacol 19,222–232 (1999).
   PubMedGoogle Scholar
• Wasef A, Dott S, Harris A et al Clin. PTchopharmacol 21,21–26 (2001).
   PubMedGoogle Scholar
• Cassey et al Presented at the Annual Meeting of the World Federation of Mental Health, Portland, OR, USA, (2001).
   Google Scholar
• Wang SL, Cavanaugh J, Shi H, Awni WA, Granneman R. Effects of divalproax sodium on aminotriptyline and nortriptyline pharmacokinetics. Clin. Pharmacol Ther. 60(1), 48–53 (1996).
   Google Scholar
• Luccena M, Blanco E, Corrales M, Berthier M. Interaction of fluoxatine an dvalproic acid. AIR I PTchiatry 155 (4), 575–577 (1998).
   Google Scholar
• Ishizaki T, Chiba K, Saito M, Kobayashi K, Iiazuka R. The effects of neuroleptics (haloperidol and chlorpromazine) on pharmacokinetics of valproic acid in schizophrenic patients. Jan. PTcophatmacol 4(5), 254–261 (1984).
   Google Scholar
• Granneman G, Scheneck D, Cavanaugh J, Witt G. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J. Clin. Bychiatry57 (5), 204–206 (1996).
   Google Scholar
• Cutrer FM, Limmoroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalgia 17(2), 93–100 (1997).
   PubMed Web of Science ®Google Scholar
• Welch KM, Chabi E, Bartosh K et al Cerebrospinal gamma-aminobutyric acid levels in migraine. BE Med 3,516–517 (1997).
   Google Scholar
• Rothrock JF, Mar KR, Yaksh TL et al Cerebrospinal fluid analysis in migraine patients and controls. Cephalagia 15,489–493 (1995).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Snaper JR, Silberstein SD et al Migraine prophylaxis with divalproex. Arch. Neural 52(3), 281–286 (1995).
   PubMed Web of Science ®Google Scholar
• Silberstein SB, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term safety of Depakote in headache prophylactic study group. Headache 41(5), 515–517 (1999).
   Google Scholar
• Kaneecki RG. A comparison of Divalproex with Propranolol and Placebo for the Prophylaxis of migraine without aura. Arch. Neural 54(9), 1141–1145 (1997).
   PubMedGoogle Scholar
• Fraitag FG, Diamond S, Diamond ML, Urban GJ. Divalproex in long-term treatment of chronic daily headache. Headache 41(3), 271–278 (2001).
   PubMedGoogle Scholar
• Northon J. Use of iv. valproate sodium in status migraine. Headache 40(9), 755–757 (2000).
   PubMedGoogle Scholar
• Mathew NT, Kailasam J, Meadors L, Chernyschev 0, Gentry P. Intravenous valproate sodium (depacone) aborts migraine rapidly: a preliminary report. Headache 40 (9), 720–723 (2000) .
   Google Scholar
• Asconape J, Penry J, Dreifuss F, Riela A, Mirza W Valproate-associated pancreatitis. Epilepsia 34,177–183 (1993).
   PubMed Web of Science ®Google Scholar
• Ford DM, Portman RJ, Lum GM. Pancreatitis in children on chronic dialysis treated with valproic acid. Perliatr Nephrol 4(3), 259–261 (1990).
   PubMedGoogle Scholar
• Bryant AE 3rd, Dreifus FE. Valproic acid hepatic fatalities. III. US experience since 1986. Neurology46(2), 465–469 (1996).
   Google Scholar
• Sugimoto T, Muro H, Woo M, Nisida N, Murakami K. Valproate metabolites in high dose valproate plus phenytoin therapy. Epilepsia 37,1200–1203 (1996).
   Google Scholar
• May RB, Sunder TR. Hematologic manifestation of long-term valproate therapy. Epilepsia 34,1098–1101 (1993).
   PubMed Web of Science ®Google Scholar
• Straussberg R, Kivity S, Weitz R, Harel L, Gadoth N. Reversible cortical atrophy and cognitive decline induced by valproic acid. Eur. Paediatr Neural 2(4), 213–218 (1998).
   Google Scholar
• Guerrini R, Belmonte A, Canapicchi R, Casalini C, Perucca E. Reversible pseudoatrophy of brain and mental deterioration associated with valproate treatment. Epilepsia 39(1), 27–32 (1998).
   PubMedGoogle Scholar
• Kifume A, Kubota F, Shibata N, Akate T, Kikuchi S. Valproic acid-induced hyperammonic encephalopathy with triphasic waves. Epilepsia 41(7), 909–912 (2000).
   PubMedGoogle Scholar
• Sheith RD,Wesolowski CA, Jacob JC et al Effect of carbamazepine and valproate on bone mineral density. I Pecliatr 127(2), 256–262 (1995).
   Google Scholar
• Herzog, A, Schachter S. Valproate and the polycystic ovarian syndrome: Final thoughts. Epilepsia 42(3), 311–315 (2001).
   PubMedGoogle Scholar
• Bauer J, Jarre A, Klingmuller D, Elger C. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res. 41(2), 163–167 (2000).
   Google Scholar
• Genton P, Bauer J, Duncan S et al On the association between valproate and Polycystic Ovary Syndrome. Epilepsia 42(3), 295–304 (2001).
   PubMedGoogle Scholar
• Murialdo G, Galimberti CA, Gianelli MV et al Effect of valproate, Phenobarbital and carbamazepine on sex steroid set-up in women with epilepsy. Clin. Neuropharmacol 21,52–58 (1998).
   PubMed Web of Science ®Google Scholar
• Morrell M. Presented at the International Epilepsy Congness, Buenos Aires, AR.
   Google Scholar
• Demir E, Aysum S. Weight gain with valproate in childhood. Perliatr Neural 22(5), 361–364 (2000).
   PubMedGoogle Scholar
• Panjehshahin MR, Bowmer CJ, Yates MS. Effect of valproic acid, its unsaturated metabolites and some structurally related fatty acids on the binding of warfarin and dansylsarcosine to human albumin. Biochem. Pharmacol 41,1227–1233 (1991).
   Google Scholar
• Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur. j Clin. Pharmacol 27(3), 341–343 (1984).
   Google Scholar
• Crawford P, Chadwick D, Cleland et al Sodium valproate and oral contraceptive steroids. Br J. Clin. Pharmacol 20, 288–289 (1985).
   Google Scholar
• Dulac 0, Stem D, Rey E, Arthius M. Sodium valproate monotherapy in childhood epilepsy. Brain Dev. 8, 47–52 (1986).
   Google Scholar
• Minagawa K, Miura H. Phenobarbithal, primidone and sodium valproate in prophylaxis in febrile convulsions. Brain Dev. 3, 385–393 (1981)
   PubMedGoogle Scholar
• Herranz JL, Armijo JA, Arteaga R. Effectivness and toxisity of phenobarbital, primidone in the prevention of febrile convulsions, controlled by plasma levels. Epilepsia 25, 89–95 (1984).
   Google Scholar
• Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 2, 937 (1982).
   PubMed Web of Science ®Google Scholar
• Diliberti J, Famdon P, Dennis N et al The fetal valproate syndrome. Am. J. Med. Gen. 19, 473–481 (1984).
   PubMed Web of Science ®Google Scholar
• Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neural Neurosurg. PFhiatty 70, 15–21 (2001).
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Tariot PN, Erb R et al Placebo-controlled study of divalproex sodium for agitation in dementia. Am. J. Geriatr Psychiatry 9, 58–66 (2001).
   PubMedGoogle Scholar
• Raskind MA. Evaluation and management of aggressive behavior in the elderly demented adult. J. Gun. Psychiatry 60\(Suppl. 5), 45–49 (1999).
   Google Scholar
• Brewster D, Muir NC. Valproate plasma protein binding in the uremic condition. Gun. Phatmacol Ther (27), 76–82 (1980).
   PubMedGoogle Scholar
• Gugler R, Mueller G. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. BE j Gun. Phatmacol 5, 441–446 (1978).
   PubMed Web of Science ®Google Scholar
• Bruni J, Wang LH, Malbury TC et al Protein binding of valproic acid in uremic patients. Neurology 30, 557–559 (1980).
   PubMedGoogle Scholar
• Klotz U, Rapp T, Mueller WA. Disposition of valproic acid in patients with liver disease. hiuj Gun. Phatmacol 13, 55–60 (1978).
   Google Scholar
• Whitton PS, Fowler U. The effect of valproic acid on 5-hydroxytriptamine and 5 hydroxy-indoleacetic acid concentration in hippocampal dyalisates in vivo. Eur. Pharmacol 200, 167 (1991).
   Google Scholar
• Kanner AM, Palac S. Depression in epilepsy: a common but often unrecognized comorbid malady. Epilepsy Behavior 1, 37–51(2000).
   PubMed Web of Science ®Google Scholar
• Yang L, Benardo LS. Valproate prevents epileptiform activity after trauma in an in vitro model in neocortical slices. Epilepsia 41, 1507–1513 (2000).
   PubMedGoogle Scholar
• Temkin NR, Dikmen ES, Anderson GD et al Valproate therapy for prevention of post traumatic seizures. A randomized trial. Neurosurg. 91, 593–600 (2000). Affiliations
   Google Scholar